UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) ...

An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Treatment with oral or inhaled corticosteroids is not warranted for children without history of atopy or family history of asthma ... received albuterol plus a 7-day course of inhaled budesonide ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

Proair HFA (albuterol sulfate) Inhalation Aerosol is supplied as a ... of deterioration of asthma and requires reevaluation of treatment. There is a pregnancy exposure registry that monitors ...

Asthma is a chronic (long-term) lung condition in which airways can become inflamed and narrowed. This makes it difficult to ...

The U.S. Centers for Medicare & Medicaid Services (CMS) has released a preliminary list of 101 generic drugs that would be ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

The IHS is supposed to provide free care to Native Americans, but it does so only at scattered clinics and hospitals the ...

AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...